PET PET
  • My Account
  • Subscribe
Become a Friend Donate
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • My Account
  • Subscribe
  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements
PETBioNewsNewsRoche attempts $5.7bn takeover of DNA sequencing firm Illumina

BioNews

Roche attempts $5.7bn takeover of DNA sequencing firm Illumina

Published 30 January 2013 posted in News and appears in BioNews 642

Author

Ruth Saunders

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.

Swiss pharmaceutical company Roche has made an unsolicited bid worth $5.7 billion to takeover US DNA sequencing firm Illumina....

Swiss pharmaceutical company Roche has made an unsolicited bid worth $5.7 billion to takeover US DNA sequencing firm Illumina.

Gene sequencing allows scientists to predict how a patient might respond to a particular drug, leading to interest from the pharmaceutical industry to develop 'personalised' medicines that target specific genes.

Illumina, a major provider of DNA sequencing technology in the US, offers machines that can decode a person's entire genome and Roche, which already supplies diagnostic tests, is the world's largest manufacturer of cancer drugs. It is believed a successful acquisition will strengthen Roche's position in the sequencing and microarrays market, which is seeing a growing demand with increased use of genetic information and techniques in healthcare.

'Our ability to offer a total solution to researchers will help enable the discovery of complex new biomarkers improving drug discovery and the selection of patients most likely to respond to a targeted treatment', said Daniel O'Day, chief operating officer at Roche Diagnostics Division.

Following Roche's announcement of its intention to make an offer, Illumina's board of directors responded by adopting a strategy to resist a hostile takeover known as a rights agreement, or the 'poison pill'. If a certain number of shares are acquired by any person or group, it allows Illumina's existing shareholders to buy any outstanding shares not bought by the takeover company at a price below fair market value. This move can force a higher offer or can deter a bid because of the higher cost of acquiring the extra shares.

'Consistent with its fiduciary duties, the Illumina Board has taken this action to ensure that our stockholders receive fair treatment and protection in connection with any proposal or offer to acquire the company, including the proposal announced by Roche', said Jay Flatley, chief executive officer of Illumina. This response indicates that its leadership is not convinced of the proposal's value, and that the investors believe the company is worth more.

Roche announced that it was 'disappointed' with Illumina's response, and its decision not to participate in further discussions of the proposed transaction.

'The poison pill would make the tender offer useless, so it's unclear what Roche would gain other than a chance to posture that it's serious', an arbitrage trader, who declined to be named, told Reuters.

This did not deter Roche who announced an official offer, to expire on 24 February 2012. The company maintained that it delivers full and fair value to Illumina's shareholders. Illumina responded by announcing that its board would carry out a review of Roche's unsolicited offer and issue recommendations for its shareholders in due course.

'The point, counter-point of a bid and then poison pill and the back-and-forth just makes this seem like a longer, drawn-out battle', another arbitrage trader who declined to be named told Reuters.

Roche has been forced to raise its offer in similar bidding situations in the past, including its takeover of biotech company Genentech and test maker Ventana, according to Reuters.

As pharmaceutical companies try to harness new technologies to develop into new areas of growth, mergers and acquisitions are seen to be common in the field. Reuters reports that biotech company Amgen has recently agreed to buy Micromet in a $1.6 billion agreement to acquire technology that uses the body's immune system to fight cancer.

Related Articles

Image by Alan Handyside via the Wellcome Collection. Depicts a human egg soon after fertilisation, with the two parental pronuclei clearly visible.
CC0 1.0
Image by Alan Handyside via the Wellcome Collection. Depicts a human egg soon after fertilisation, with the two parental pronuclei clearly visible.
News
27 June 2014 • 1 minute read

Second IVF company to be floated sees share prices grow

by Ayesha Ahmad

An Australian fertility company has seen the price of its shares rise on the first day of its public listing on the stock market....

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
27 February 2013 • 2 minutes read

Roche withdraws bid for DNA sequencing pioneer Illumina

by Ruth Saunders

The standoff between Roche and Illumina, which provides services and equipment for genetic analysis, finally came to an end last week as the Swiss pharmaceuticals giant ended efforts for a hostile takeover bid...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
24 January 2013 • 2 minutes read

Desktop machine can sequence a genome in one day for £650

by Zara Mahmoud

A US biotechnology firm has unveiled an automated desktop DNA sequencer that can decode the sequence of the human genome in one day for as little as $1,000 (£650). Given its first public viewing at a consumer electronics show in Las Vegas, Life Technologies Corporation's Ion Proton sequencer uses microchips similar to those found in digital cameras...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
12 December 2012 • 1 minute read

Faroe Islands to be the first to sequence an entire nation

by Oliver Timmis

The Faroe Islands is set to become the first region to sequence the genome of its entire population....

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
19 November 2012 • 2 minutes read

Genetic mystery solved as the first Briton has their whole genome sequenced

by Dr Jay Stone

Four-year-old Katie Warner from Oxford has become the first person in Britain to have her whole genome sequenced in order to locate the mutation that causes her skull abnormality...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
6 September 2010 • 3 minutes read

NHS laboratory aims to pilot next-generation genetic sequencing within two years

by Dr Vivienne Raper

Genetic testing for some inherited diseases using ultra-fast next generation DNA sequencers could be piloted by some NHS clinical laboratories within two years...

Leave a Reply Cancel reply

You must be logged in to post a comment.

« Report examines genomic medicine on the NHS

Data-Label The UK's Leading Supplier Of Medical Labels & Asset Labels

RetiringDentist.co.uk The UK's Leading M&A Company.

Find out how you can advertise here
easyfundraising
amazon

This month in BioNews

  • Popular
  • Recent
13 June 2022 • 2 minutes read

Drop in diversity of blood stem cells leads to old-age health issues

8 August 2022 • 2 minutes read

Placenta and organ formation observed in mouse embryo models

8 August 2022 • 2 minutes read

Complex structures of the human heart bioengineered

8 August 2022 • 1 minute read

Brain tumour gene also linked to childhood cancers

8 August 2022 • 2 minutes read

Lower hormone doses may improve IVF egg quality

8 August 2022 • 2 minutes read

Boosting muscle cell production of gene therapy proteins

Subscribe to BioNews and other PET updates for free.

Subscribe
  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856

Subscribe to BioNews and other PET updates for free.

Subscribe
PET PET

PET is an independent charity that improves choices for people affected by infertility and genetic conditions.

  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Navigation

  • About Us
  • Get Involved
  • Donate
  • BioNews
  • Events
  • Engagement
  • Jobs & Opportunities
  • Contact Us

BioNews

  • News
  • Comment
  • Reviews
  • Elsewhere
  • Topics
  • Glossary
  • Newsletters

Other

  • My Account
  • Subscribe

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856